Science: psychedelic science, curated weekly

Every week our machine elves read every new psychedelic science paper on PubMed, every new preprint (via Europe PMC) and every trial registration on ClinicalTrials.gov. An editor picks the few that matter and says plainly how strong the evidence is: animal or human, controlled or not, peer reviewed or preprint.

The Science section has three parts: this week's issue, a searchable library of everything our machine elves have collected, and a research chat that answers questions from the literature and cites its sources.

This week: Launch issue: the first 10 weeks

Every new psychedelic science paper, preprint and trial registration since late July: what mattered and what did not hold up.

  1. Psilocybin prevented chemotherapy nerve damage in mice
  2. A placebo-controlled psilocybin trial inside England's NHS
  3. On psilocybin, brain activity lines up with the surroundings
  4. One mushroom makes both psilocybin and death-cap toxins
  5. Oregon's legal psilocybin services: first safety and outcome data
  6. Zurich's real-world psilocybin results trail the trials
  7. Do you need the trip for the benefit?
  8. Chemists are redesigning psychedelics for safety
  9. Microdosing doesn't beat placebo in healthy adults
  10. Early pilots in veteran PTSD, phantom limb pain and bipolar II
  11. 20 new trials registered
  12. Big Pharma and the FDA move
—
Node—
Statuslive
Throughput—